The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
Abstract
Background The use of abacavir--a potent HIV-1 nucleoside-analogue reverse-transcriptase inhibitor--is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases. Genetic factors influencing the immune response to abacavir might confer susceptibility. We aimed to find associations between MHC alleles and abacavir hypersensitivity in HIV-1-positive individuals treated with abacavir.Methods MHC region typing was done in the first 200 Western Australian HIV Cohort Study participants exposed to abacavir. Definite abacavir hypersensitivity was identified in 18 cases, and was excluded in 167 individuals with more than 6 weeks' exposure to the drug (abacavir tolerant). 15 individuals experienced some symptoms but did not meet criteria for abacavir hypersensitivity. p values were corrected for comparisons of multiple HLA alleles (p(c)) by multiplication of the raw p value by the estimated number of HLA alleles present within the loci examined.Findings HLA-B*5701 was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir tolerant patients (odds ratio 117 [95% CI 29-481], p(c)<0.0001), and the HLA-DR7 and HLA-DQ3 combination was found in 13 (72%) of hypersensitive and five (3%) of tolerant patients (73 [20-268], p(c)<0.0001 ). HLA-B*5701, HLA-DR7, and HLA-DQ3 were present in combination in 13 (72%) hypersensitive patients and none of the tolerant patients (822 [43-15 675], p(c)<0.0001). Other MHC markers also present on the 57.1 ancestral haplotype to which the three markers above belong confirmed the presence of haplotype-specific linkage disequilibrium, and mapped potential susceptibility loci to a region bounded by C4A6 and HLA-C. Within the entire abacavir-exposed cohort (n=200), presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 had a positive predictive value for hypersensitivity of 100%, and a negative predictive value of 97%.Interpretation Genetic susceptibility to abacavir hypersensitivity is carried on the 57.1 ancestral haplotype. In our population, withholding abacavir in those with HLA-B*5701, HLA-DR7, and HLA-DQ3 should reduce the prevalence of hypersensitivity from 9% to 2.5% without inappropriately denying abacavir to any patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2002, Mallal et al. showed the most prevalent Southeast Asian population HLA complex, HLA-B*57:01, correlated with abacavir sensitivity [103].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [103]
Citations
Cites
ANKYLOSING SPONDYLITIS AND HL-A 27
Brewerton, D. A., Hart, F. D., Nicholls, A., Caffrey, M., James, D. C. O., & Sturrock, R. D. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91360-3 · Cited by 1,836
High-resolution haplotype structure in the human genome
Daly, M. J., Rioux, J. D., Schaffner, S. F., Hudson, T. J., & Lander, E. S. (2001) · Nature Genetics · doi:10.1038/ng1001-229 · Cited by 1,717
Haplotype tagging for the identification of common disease genes
Johnson, G. C. L., Esposito, L., Barratt, B. J., Smith, A. N., Heward, J., Di Genova, G., Ueda, H., Cordell, H. J., Eaves, I. A., Dudbridge, F., et al. (2001) · Nature Genetics · doi:10.1038/ng1001-233 · Cited by 1,174
Wilson, A. G., di Giovine, F. S., Blakemore, A. I. F., & Duff, G. W. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.5.353 · Cited by 881
HLA and disease associations: Detecting the strongest association
Svejgaard, A., & Ryder, L. P. (1994) · Tissue Antigens · doi:10.1111/j.1399-0039.1994.tb02291.x · Cited by 423
Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., & Steel, H. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 406
Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase
Johnson, A. A., Ray, A. S., Hanes, J., Suo, Z., Colacino, J. M., Anderson, K. S., & Johnson, K. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106743200 · Cited by 403
Disease Associations with Complotypes, Supratypes and Haplotypes
Dawkins, R. L., Christiansen, F. T., Kay, P. H., Garlepp, M., Mccluskey, J., Hollingsworth, P. N., & Zilko, P. J. (1983) · Immunological Reviews · doi:10.1111/j.1600-065x.1983.tb00707.x · Cited by 274
Self-citationZanni, M. P., von Greyerz, S., Schnyder, B., Brander, K. A., Frutig, K., Hari, Y., Valitutti, S., & Pichler, W. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3544 · Cited by 238
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
Faletto, M. B., Miller, W. H., Garvey, E. P., St Clair, M. H., Daluge, S. M., & Good, S. S. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1099 · Cited by 224
Cited by
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
Self-citationPharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Uncovering the roles of rare variants in common disease through whole-genome sequencing
Cirulli, E. T., & Goldstein, D. B. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2779 · Cited by 1,136
“In another example, the frequency of the risk factor human leukocyte antigen-B*5701 ( HLA-B*5701 ) is increased as much as 30-fold in individuals who are hypersensitive to the antiretroviral drug abacavir compared with the general populatio”
Background
Metadata
- Authors
- Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., & Christiansen, F.
- Affiliations
- Murdoch University (AU)
- Royal Perth Hospital (AU)
- Corresponding author
- Mallal, S
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9308
- Pages
- 727-732
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2140055542
- Cited by
- 1,380
- References
- 21
- Citations by year
- 2026: 9 · 2025: 26 · 2024: 28 · 2023: 28 · 2022: 48 · 2021: 47 · 2020: 42 · 2019: 65 · 2018: 56 · 2017: 76 · 2016: 74 · 2015: 80 · 2014: 66 · 2013: 71 · 2012: 76
- FWCI
- 31.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- abacavir hypersensitivity, HLA-B*57:01, HLA-DR7, HLA-DQ3, HIV-1 reverse transcriptase inhibitors, drug hypersensitivity, MHC alleles, genetic susceptibility, linkage disequilibrium, HLA haplotypes, HIV-1 infection
- MeSH terms
- Abacavir, Adult, Alleles, Drug Hypersensitivity, Female, Gene Frequency, Genetic Markers, Haplotypes, HLA-DQ Antigens, Humans, Male, Middle Aged, Dideoxynucleosides, HLA-B Antigens, Cohort Studies, HIV-1, HIV Infections, HLA-DR7 Antigen, Reverse Transcriptase Inhibitors, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. https://app.cochat.ai/papers/10.1016/s0140-6736(02)07873-x
- The paper
- Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., & Christiansen, F. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet. https://doi.org/10.1016/s0140-6736(02)07873-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.